Interleukin Genetics Raises $10 Million in Financings

The syndicate is comprised of new and existing investors including two leading life sciences investment firms, New Enterprise Associates and Bay City Capital. Pursuant to the purchase agreement, the Company has agreed to issue an aggregate of 50,099,700 shares of the Company's common stock at a price per share of $0.1003, as well as warrants to purchase up to an aggregate of 50,099,700 shares of common stock.

http://ift.tt/1CE0YEa